Purpose of review MicroRNAs (miRNAs) regulate gene expression by binding to target mRNAs and control a wide range of biological functions. Recent reports have identified specific miRNAs as major regulators of fatty acid and cholesterol homeostasis. This review examines the biological function of various miRNAs and the emerging evidence linking specific miRNAs to critical pathways in lipid metabolism.
INTRODUCTION
MiRNAs comprise a class of small noncoding RNAs approximately 22 nucleotides in length and were first discovered in Caenorhabditis elegans as regulators of development [1] . MiRNAs control a large portion of the human genome by binding to hundreds of mRNAs [2] , thus underling the significant role miRNAs can play in post-transcriptional regulation. Bioinformatic analysis has suggested that one miRNA alone can regulate the expression of over a thousand mRNAs [3] . In doing so, miRNAs have been shown to play roles in cell proliferation [4] , apoptosis [5] , cardiogenesis [6] , lymphocyte development [7] , adipocyte differentiation [8] and insulin secretion [9] . In addition, miRNA regulation of gene expression has been implicated in a variety of diseases including obesity, cancer, atherosclerosis and diabetes [9] [10] [11] . Recent studies also suggest a role for miRNAs in regulating fatty acid (FA) and cholesterol homeostasis [12] [13] [14] . This review will focus on miRNA regulation of cholesterol and FA metabolism, adipogenic miRNAs involved in lipid metabolism, and newly discovered miRNAs that play novel roles in regulating metabolic pathways.
MIRNAS AS POST-TRANSCRIPTIONAL REGULATORS OF GENE EXPRESSION
In humans, miRNA precursors are synthesized by RNA polymerase II as a pri-miRNA and subsequently cleaved in the nucleus by a ribonuclease III (RNase III) termed Drosha to form premRNA [15] . The pre-miRNA is exported into the cytoplasm by exportin 5, wherein it is processed into a miRNA/miRNA duplex and subsequently into a mature single stranded miRNA by another RNase III named Dicer. The mature miRNA is incorporated into the RNA-inducing silencing complex (RISC) [16] , which assists imperfect binding to complimentary sequences, most commonly on the 3 0 untranslated region (UTR) of target mRNA. This binding allows regulation of mRNAs at the post-transcriptional level by inducing translational suppression/reduced protein synthesis and/or mRNA degradation. MiRNAs have been shown to negatively regulate mRNA expression in three ways by mRNA degradation via deadenylation of the 3'UTR, translational repression and sequestering mRNA from ribosomes into processing bodies [2, 17, 18] . Although it is conventionally thought that miRNAs target the 3 0 UTR to downregulate gene expression, there is evidence that miRNAs can also regulate mRNA expression in alternative ways. Some miRNAs target the coding regions or the 5 0 UTR to regulate gene expression whereas others can positively activate mRNA translation [18] [19] [20] . Further understanding of miRNA binding and targeting mechanisms will help reveal ways in which miRNAs regulate gene expression and metabolic pathways.
IDENTIFICATION OF SPECIFIC MIRNAS CONTROLLING CHOLESTEROL AND FATTY ACID METABOLISM
The best-known example of a miRNA involved in lipid regulation is miR-33. In humans, miR-33a and miR-33b are encoded by the SREBP genes Srebf2 and Srebf1, respectively. In mice, the existence of only one miR-33 within the Srebf2 gene is evident, which is comparable to the human miR-33a [21] . This finding highlights the evolutionary conservation of miR-33a between species [22] . Reports emphasize the ability of miR-33 to regulate cholesterol homeostasis by targeting conserved sequences in the 3 0 UTR of both Abca1 and Abcg1 [22, 23] . In sterol depleted states, miR-33 downregulates Abca1 and Abcg1 in an attempt to raise intracellular cholesterol levels. This is accomplished by impairment of HDL biogenesis (Table 1 ) because of restricted cholesterol efflux to apoA1 and to nascent HDL [22, 23] . Conversely, inhibition of miR-33 in mice increases expression of Abca1 and Abcg1 and stimulates an associated increase in cholesterol efflux to apoA1 thus promoting reverse cholesterol transport [23] . A recent study in LDL null mice demonstrated that antagonism of miR-33 increased cholesterol efflux from macrophages into serum, liver and feces, with a drastically heightened level ($82%) of fecal sterol excretion. Additionally, miR-33 inhibition reduced lipid accumulation in arterial plaques and raised circulating HDL levels [24] . The relevance of these results is difficult to establish with respect to humans or larger animals because of the fact that miR-33b is nonexistent in mice. A recent study involving treatment of African green monkeys can more accurately represent miR-33 regulation in humans. In this study, an antisense oligonucleotide (ASO) targeting both miR-33a and miR-33b enhanced expression of hepatic Abca1 and increased plasma HDL levels, as supported by previous experiments in mice [25 && ]. Additionally, miR-33 enhanced expression of FA oxidation mRNAs (Crot, Cpt1a, Hadhb and Prkaa1) and reduced expression of FA synthesis mRNAs (Srebf1, Fasn, Acly and Acaca). These changes in mRNA expression led to suppression of VLDL abundance as indicated by decreased apoB levels and decreased plasma VLDL-associated TG levels [25 && ], a novel finding that has not yet been observed in mice. These studies suggest that pharmacological inhibition of miR-33a and miR-33b could be a potential therapeutic strategy given that decreased levels of HDL and increased levels of TG are associated with metabolic syndrome and atherosclerosis [36] [37] [38] [39] .
Mir-122 is the most abundantly expressed miRNA in the liver and one of the first miRNAs to be studied in regards to hepatic function [40] . A role for miR-122 in lipid metabolism was revealed in knockdown studies [26, 27] . MiR-122 inhibition by ASO in mice resulted in increased hepatic FA oxidation and decreased hepatic FA and cholesterol synthesis. In addition, miR-122 inhibition reduced total plasma cholesterol by 25-35% and this was reflected by changes in both the LDL and HDL fractions [26] . A study in African green monkeys has highlighted the value of miR-122 as a drug target wherein inhibition caused a dose dependent decrease in plasma cholesterol without any signs of toxicity [27] . Due to the lack of toxicity, miR-122 has become a strong candidate as a therapeutic target in the treatment of hypercholesterolemia in humans [27] . This approach is also currently being investigated for the treatment of hepatitis C virus infection because of a study showing antagonism of miR-122 as an effective therapy in chimpanzees [41] . Thus
KEY POINTS
MiR-33 expression is associated with decreased plasma VLDL-triglyceride (TG) levels and increased HDL cholesterol levels.
MiR-370 indirectly regulates lipogenesis by upregulating the expression of miR-122.
MiR-613 links sterol regulatory element-binding protein (SREBP) expression to liver X receptor (LXR) in a negative autoregulatory feedback loop.
Post-transcriptional regulation of mammalian LDLRAP1 gene expression is controlled by the exogenous plant derived miR-168a.
far, reports have emphasized the ability of miR-122 inhibition to significantly reduce circulating cholesterol levels and decrease FA synthesis. To further corroborate these results, an overexpression study showed that miR-122 can enhance expression of proteins involved in hepatic cholesterol synthesis (HMGRCS1, SQLE, DHCR7) [42] . Whether these mRNAs are direct targets of miR-122 remains undetermined and target mRNA sequences of miR-122 remain unidentified.
Another key miRNA regulator of lipid metabolism is miR-370 that can regulate lipid metabolism both directly and indirectly through another miRNA [28] . MiR-370 directly targets the 3 0 UTR of Cpta inducing translational repression and downregulating the rate of FA b-oxidation. More importantly, miR370 was shown to indirectly upregulate lipogenesis by initial activation of miR-122, which subsequently regulates mRNAs involved in FA and TG biosynthesis (Srebp-1c, Dgat2, Fas and Acc1) [28] . These mRNAs are thought to be indirect targets of miR-122 and the intermediate steps involved remain unknown.
ROLE OF ADIPOGENIC MIRNAS IN CONTROL OF LIPID METABOLISM
A number of miRNAs initially identified to regulate adipogenesis and adipocyte differentiation are now being implicated in modulation of FA and cholesterol metabolism. MiR-378/378Ã is an miRNA duplex shown to be highly induced during adipogenesis. Overexpression of miR-378/378Ã increased FA synthase (FAS) expression and de novo lipogenesis thus resulting in adipocyte TG accumulation [29] . In addition, ASO knockdown of miR-378 and miR-378Ã caused a reduction in TG and phospholipid synthesis. Whether or not the observed effects on lipogenesis are because of miR-378 or miR-378Ã remains undetermined. This is because of the fact that disruption of the duplex influences both the stability and expression of each strand [29] . Despite this obstacle, it is suggested that each miRNA makes independent contributions to lipid metabolism however, further studies need to be carried out to clarify independent roles. In addition to miR-378/ 378Ã, miR-27 acts as a negative regulator of adipogenesis and plays a key role in lipid metabolism. The Cholesterol synthesis Mice [26] African green monkeys [27] miR-370 Fatty acid and triglyceride biosynthesis HepG2 Cells [28] miR-378-378Ã Fatty acid and triglyceride biosynthesis 3T3-L1 and ST2 Cells [29] miR-27 Fatty acid synthesis hMADS cells [30] Lipoprotein lipase activity hMADS cells [30] 3T3-L1 cells [31] importance of miR-27 in relation to adipocytes was revealed by an overexpression study in which miR-27 abrogated expression of essential proteins was involved in adipogenesis (PPARg and C/EBPa) and had an associated inhibition of adipogenic differentiation [30, 31, 43] . Accompanying its role in adipogenesis, reports emphasize the ability of miR-27 to regulate TG and cholesterol levels. Both miR-27a and miR-27b negatively regulate LPL expression; the rate-limiting enzyme involved in hydrolysis of TG in circulating VLDL and chylomicrons [30, 31] . MiR-27a and miR-27b can also act independently such that miR-27b represses mRNAs coding for proteins involved in lipid metabolism including SREBP-1c [30, 31] and miR-27a decreases TRb1 [44] , a response associated with a reduction of cholesterol and TG [45] . A study showing increased levels of both miR-27a and miR-27b in obese mice is the first to demonstrate that obesity can elevate miRNA levels [43] . Other diseases, such as atherosclerosis, may also involve alterations in miRNA levels with potentially positive or negative effects on the pathological progression of the disease. Finally, miR-103 and miR-107 are encoded within the intron of pantothenate kinase (Pank) genes which encode the rate limiting enzyme in the synthesis of coenzyme A. Coenzyme A is important for FA metabolism and thus miR-103 and miR-107 are thought to play a role in lipid metabolism [46] . Conversely, other studies found that miR-103 and miR-107 expression levels do not correlate with that of their host genes [47] . One study has reported that ectopic expression of miR-103 accelerated adipogenesis, as indicated by increased TG accumulation [46] . Furthermore, both miR-103 and miR-107 are upregulated in obese mice and are shown to regulate insulin sensitivity [48] . Whether or not miR-103 and miR-107 are involved in lipid metabolism is currently undetermined.
NOVEL FUNCTIONS FOR NEWLY DISCOVERED MIRNAS
Further research has recently revealed novel roles for a number of other miRNAs in regulating lipid metabolism. One such way is the regulation of lipids imported into dendritic cells. miR-29a has been recently shown to enhance scavenger receptors important for mediation of lipid uptake at the cell surface of dendritic cells [32 & ]. Similar to miR-27, miR-29a also directly targets LPL and is shown to alter dendritic cell lipid composition by increasing total and esterified cholesterol levels [32 & ]. Another recent study provided novel data to suggest involvement of miR-302a in hepatic and FA metabolism [33] . In LDL À/À mice fed on a Western type diet, miR-302a expression was repressed and led to increased Abca1 and Elovl6 hepatic mRNA expression [33] . ELOVL6 is a critical enzyme involved in the rate-limiting step of the formation of long chain FAs [49] . Although many other miRNAs have been shown to target ABCA1, to our knowledge this is the first miRNA to target the ELOVL6.
The idea of SREBP proteins regulating miRNAs was previously unheard of until a recent discovery that hsa-miR-613 expression was induced by SREBP-1c [34 && ]. This study demonstrated an SREBP-1c mediated induction of LXR by hsa-miR-613. Interestingly, hsa-miR-613 was shown to bind to the 3 0 UTR of human Lxra. This led to negative regulation of Lxra expression by both hsa-miR-613 and SREBP-1c [34 && ]. Hsa-miR-613 and SREBP-1c are proposed to be involved in a negative autoregulatory feedback loop along with LXR response elements which positively regulate Lxra gene expression [34 && ]. Given that impaired Lxra gene expression is associated with a decrease in FA biosynthesis [50] , it is presumed that miR-613 plays a role in FA metabolism, however there is currently no direct evidence.
A study published this year on miR-168a presents perhaps the most intriguing and robust discovery in regards to lipid regulation via exogenous miRNAs. MiR-168a is a plant-derived miRNA abundant in rice and acquired orally through food intake [35 && ]. MiR-168a withstands acidification of the gastrointestinal tract and subsequently enters into circulation wherein it uses microvesicles (MVs) to remain present and stable in the plasma and sera of mammals. MVs shed from the membrane of a host cell and mediate transportation of lipids, miRNA or proteins to a recognized target cell [51] . MiR-168a located within Caco-2 cell-derived MVs was able to cause a reduction in the protein levels of LDL receptor adaptor protein 1 (LDLRAP1) in recipient human hepatocarcinoma HepG2 cells [35 && ]. Plant miRNAs differ from mammalian miRNA such that they require near-perfect or perfect complementarity to the nucleotide sequence of the target gene [52] . The uncovering of a near-perfect complementarity identified between miR-168a and LDLRAP1 suggests that miR-168 directly targets LDLRAP1 gene expression levels [35 && ]. This was further supported by an experiment wherein addition of exogenous miR-168a led to inhibition of LDLRAP1 expression in mouse liver. Reduced LDLARP1 resulted in decreased endocytosis of LDL by hepatic cells and caused elevated levels of plasma LDL cholesterol [35 && ]. The cross-kingdom regulation of mammalian lipid metabolism unmasks the extensive capabilities of miRNA regulation, revealing an intriguing role for nutritionally delivered miRNAs in regulation of endogenous lipid metabolic pathways.
CONCLUSION
MiRNAs are increasingly recognized as critical regulators of lipid homeostasis however, our current understanding of the roles and mechanisms involved is extremely limited. As indicated in Table 1 , miRNAs target and control different pathways involved in FA and cholesterol metabolism. There is little doubt that there are many additional miRNAs involved in regulation of lipids that are yet to be uncovered. Despite the promise of miRNAs as potential drug targets, development of miRNAs as therapeutics faces numerous challenges including target identification, specificity, mode of delivery, and length of action [13] . Further studies addressing these issues will be essential prior to clinical trials. The effectiveness of antimiR-122 in phase I clinical trials indicates the potential feasibility of miRNA mimics and/or inhibitors as treatments for dyslipidemia. MiRNA-based therapeutics hold considerable promise in the treatment of lipid and lipoprotein disorders commonly observed in participants with obesity, metabolic syndrome and type 2 diabetes.
